ClinicalTrials.gg
CompletedNCT04196777Updated Sep 19, 2024Results posted

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

An interventional study of Audit-and-feedback in Urologic Diseases and Antibacterial Drug Adverse Reaction, sponsored by Iowa City Veterans Affairs Medical Center. Completed at 3 sites in United States. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Iowa City Veterans Affairs Medical Center · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
525
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Urologic Diseases with a site in United States — 15 open to participants now, 26 under way, 9 of them phase 3. Urologic Diseases · United States.

Enrollment
6th of 70
525 · median 58
Started
2022
with 8 others
No phase
23 of 80
2 open now
Registered
44th of 80
by date

Among the 80 studies in Urologic Diseases with a site in United States, this one is the 6th largest by enrollment of the 70 interventional ones that give a count, is one of 9 that started in 2022, is one of 23 with no phase, and was the 44th registered.

Urologic Diseases

221 studies on the registry are indexed under Urologic Diseases; 48 are open to participants now.

Browse Urologic Diseases studies →

Open to participants now

15 of the 80 studies in Urologic Diseases with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Urologic Diseases studies recruiting now, 24 (65%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Urologic Diseases with a site in United States, or all of them as a file.
02

Study summary

Antimicrobial resistance is one of today''s most urgent public health problems. An important strategy to slow the spread of antimicrobial resistance is the promotion of judicious antimicrobial use. There are many opportunities to reduce unnecessary antimicrobial-prescribing, including in patients undergoing surgical procedures. The following study will specifically study opportunities to improve antimicrobial use in patients undergoing common urologic procedures at hospitals in the Veterans Health Administration (VHA).

Guidelines recommend giving antibiotics for no more than 24-hours after most urologic procedures, but the investigators have shown that the unnecessary use of post-procedural antimicrobials is common in this setting. In a national cohort of nearly 30,000 VHA patients, excessive post-procedural antimicrobials were prescribed after 37.2% of urologic procedures for a median duration of 3.0 excess days.

In this study, the investigators will evaluate whether giving regular feedback to providers at 3 VHA hospitals can reduce unnecessary antimicrobial use after urologic procedures.

Read the detailed description

Trial design: The investigators propose a before/after quasi-experimental design, which will be analyzed with an interrupted time-series analysis.

Participants: There will be 3 intervention VHA hospitals. To be eligible, a VHA hospital must perform the following 3 urologic procedures: transurethral resection of the prostate (TURP), transurethral resection of a bladder tumor (TUBRT), and ureteroscopy (URS).

Interventions: The study team will conduct an audit-and-feedback intervention focused on the unnecessary use of prolonged antimicrobial therapy after common urologic procedures.

The audit-and-feedback intervention will target the urology providers at the 3 intervention sites.

Outcomes: The primary outcome for this study will be the frequency of excessive post-procedural antimicrobial-prescribing in the 3 urologic procedures of interest. Secondary outcomes include several safety outcomes, such as late antimicrobial prescriptions, return visits, mortality, C. difficile testing and C. difficile infection.

For each site, the pretest period will be the 2-years prior to the intervention. The intervention itself will last 1-year.

Selection of sites: Intervention sites will be randomly selected from the top quartile of all sites, as ranked on the frequency of excessive post-procedural antimicrobial-prescribing. If sites refuse to participate, additional sites will be invited until 3 sites agree to be enrolled.

Statistical methods: At the conclusion of the pilot trial, a quasi-experimental interrupted time-series (ITS) analysis will be performed to assess the change in monthly antimicrobial use for the 3 intervention sites combined. The time frame for this ITS analysis will be the two-years prior to the pilot trial's initiation through the trial's 1-year intervention period for a total of 36 months.

03

Conditions studied

  • Urologic Diseases
  • Antibacterial Drug Adverse Reaction

Browse trials for

Keywords

  • anti-bacterial
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • A practicing urologist at an intervention site, OR
  • A member of the antimicrobial stewardship team at an intervention site

Exclusion Criteria: None

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
525 participants (actual)

Study arms

  • Experimental
    Intervention

    We will randomly select 3 intervention sites from the top quartile of all VHA sites, as ranked by the frequency of excessive post-procedural antimicrobial use after the 3 urologic procedures of interest. We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be shared at baseline with the intervention sites. Updated data will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail. These data will include an anonymous comparison to all other VHA hospitals.

    Behavioral: Audit-and-feedback

Interventions

  • BehavioralAudit-and-feedback

    We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. At first, we will schedule one-on-one conference calls with urology providers and the antimicrobial stewardship team at each of the 3 intervention sites. These conference calls will include a review of guidelines, a review of the facility's data on excessive post-procedural antimicrobial use for urologic patients, and an anonymous comparison to all other VHA sites. Next, we will prospectively monitor excessive post-procedural antimicrobial use at all 3 sites and the entire VHA for 1 year. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail.

06

What researchers measure

Primary outcomes

  1. Percentage of Cases Who Received Excessive Post-procedural Antimicrobials

    Excessive post-procedural antimicrobial use is defined as a prescription for a antimicrobial agent on post-procedural day one. For this specific outcome measure, the numerator will be the number of patients who received an excessive post-procedural antimicrobial, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

    Time frame: Within 1 day of the urologic procedure

Secondary outcomes

  1. Excessive Post-procedural Antimicrobial Duration (Mean)

    Excessive post-procedural antimicrobial duration is defined as the duration of continuous excessive post-procedural antimicrobial use, as quantified as days of therapy per National Healthcare Safety Network methodology. This outcome will be calculated for each patient who underwent a qualifying procedure and received a post-procedural antimicrobial (primary outcome).

    Time frame: Within 30-days of the urologic procedure

  2. Percentage of Cases Who Received a Late Antimicrobial Prescription

    Late antimicrobial prescription is defined as the prescription of a designated antimicrobial that does not qualify as a post-procedural antimicrobial (see above) by any provider within 7-30 days of the date of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who received a late antimicrobial, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

    Time frame: Within 30-days of the urologic procedure

  3. Percentage of Cases Who Were Re-admitted to the Hospital or Presented to an Emergency Department or an Urgent Care Clinic

    Return visits: sought urgent/emergent healthcare for any indication within 30 days of the patient's index urologic procedure. For this specific outcome measure, the numerator will be the number of patients who had a return visit for any reason within 30-days of the urologic procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

    Time frame: Within 30-days of the urologic procedure

  4. Percentage of Cases Who Died (Mortality)

    Mortality: all-cause death within 30-days of the patient's index urologic procedure. For this specific outcome measure, the numerator will be the number of patients who died for any reason within 30-days of the urologic procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

    Time frame: Within 30-days of the urologic procedure

  5. Percentage of Cases Who Underwent Clostridioides Difficile Testing

    Clostridioides difficile testing is defined as any laboratory test ordered for C. difficile within 30-days of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who underwent C. difficile testing within 30-days of the procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

    Time frame: Within 30-days of the urologic procedure

  6. Percentage of Cases Who Acquired Clostridioides Difficile Infection

    Clostridioides difficile infection (CDI) is defined as a positive laboratory test for C.difficile within 30-days of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who had a positive test for C. difficile within 30-days of the procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

    Time frame: Within 30-days of the urologic procedure

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneIntervention
Started525
Completed525
Not completed0

Outcome measures

PrimaryPercentage of Cases Who Received Excessive Post-procedural Antimicrobials

Excessive post-procedural antimicrobial use is defined as a prescription for a antimicrobial agent on post-procedural day one. For this specific outcome measure, the numerator will be the number of patients who received an excessive post-procedural antimicrobial, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

Time frame:
Within 1 day of the urologic procedure
Reported as:
Count of participants · Participants
Percentage of Cases Who Received Excessive Post-procedural Antimicrobials
ParticipantsInterventionBaseline Period
Percentage of Cases Who Received Excessive Post-procedural Antimicrobials216644
Statistical analysis
  • Intervention vs Baseline Period · Regression, Logistic · p = 0.004 · Odds ratio (or): 0.089 · 95% CI 0.016 to 0.445
  • Intervention vs Baseline Period · Regression, Logistic · p = 0.259 · Odds ratio (or): 1.593 · 95% CI 0.710 to 3.585
  • Intervention vs Baseline Period · Regression, Logistic · p = 0.738 · Odds ratio (or): 0.748 · 95% CI 0.135 to 4.147
SecondaryExcessive Post-procedural Antimicrobial Duration (Mean)

Excessive post-procedural antimicrobial duration is defined as the duration of continuous excessive post-procedural antimicrobial use, as quantified as days of therapy per National Healthcare Safety Network methodology. This outcome will be calculated for each patient who underwent a qualifying procedure and received a post-procedural antimicrobial (primary outcome).

Time frame:
Within 30-days of the urologic procedure
Reported as:
Mean · Days of antimicrobial therapy
Excessive Post-procedural Antimicrobial Duration (Mean)
Days of antimicrobial therapyInterventionBaseline
Excessive Post-procedural Antimicrobial Duration (Mean)4.1 ± 6.45.3 ± 6.4
Statistical analysis
  • Intervention · Wilcoxon (Mann-Whitney) · p = 0.001 · Rank sum test statistic: 1280.5
  • Intervention vs Baseline · Wilcoxon (Mann-Whitney) · p = 0.013 · Rank sum test statistic: 28662
  • Intervention vs Baseline · Wilcoxon (Mann-Whitney) · p = 0.14 · Rank sum test statistic: 784
SecondaryPercentage of Cases Who Received a Late Antimicrobial Prescription

Late antimicrobial prescription is defined as the prescription of a designated antimicrobial that does not qualify as a post-procedural antimicrobial (see above) by any provider within 7-30 days of the date of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who received a late antimicrobial, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

Time frame:
Within 30-days of the urologic procedure
Reported as:
Count of participants · Participants
Percentage of Cases Who Received a Late Antimicrobial Prescription
ParticipantsInterventionBaseline Period
Percentage of Cases Who Received a Late Antimicrobial Prescription83169
Statistical analysis
  • Intervention vs Baseline Period · Regression, Logistic · p = 0.04 · Odds ratio (or): 0.76 · 95% CI 0.58 to 0.99
SecondaryPercentage of Cases Who Were Re-admitted to the Hospital or Presented to an Emergency Department or an Urgent Care Clinic

Return visits: sought urgent/emergent healthcare for any indication within 30 days of the patient's index urologic procedure. For this specific outcome measure, the numerator will be the number of patients who had a return visit for any reason within 30-days of the urologic procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

Time frame:
Within 30-days of the urologic procedure
Reported as:
Count of participants · Participants
Percentage of Cases Who Were Re-admitted to the Hospital or Presented to an Emergency Department or an Urgent Care Clinic
ParticipantsInterventionBaseline Period
Percentage of Cases Who Were Re-admitted to the Hospital or Presented to an Emergency Department or an Urgent Care Clinic113186
Statistical analysis
  • Intervention vs Baseline Period · Regression, Logistic · p = <0.01 · Odds ratio (or): 0.68 · 95% CI 0.53 to 0.87
SecondaryPercentage of Cases Who Died (Mortality)

Mortality: all-cause death within 30-days of the patient's index urologic procedure. For this specific outcome measure, the numerator will be the number of patients who died for any reason within 30-days of the urologic procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

Time frame:
Within 30-days of the urologic procedure
Reported as:
Count of participants · Participants
Percentage of Cases Who Died (Mortality)
ParticipantsInterventionBaseline Period
Percentage of Cases Who Died (Mortality)44
SecondaryPercentage of Cases Who Underwent Clostridioides Difficile Testing

Clostridioides difficile testing is defined as any laboratory test ordered for C. difficile within 30-days of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who underwent C. difficile testing within 30-days of the procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

Time frame:
Within 30-days of the urologic procedure
Reported as:
Count of participants · Participants
Percentage of Cases Who Underwent Clostridioides Difficile Testing
ParticipantsInterventionBaseline Period
Percentage of Cases Who Underwent Clostridioides Difficile Testing16
SecondaryPercentage of Cases Who Acquired Clostridioides Difficile Infection

Clostridioides difficile infection (CDI) is defined as a positive laboratory test for C.difficile within 30-days of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who had a positive test for C. difficile within 30-days of the procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.

Time frame:
Within 30-days of the urologic procedure
Reported as:
Count of participants · Participants
Percentage of Cases Who Acquired Clostridioides Difficile Infection
ParticipantsInterventionBaseline Period
Percentage of Cases Who Acquired Clostridioides Difficile Infection00

Adverse events

Collected over We monitored for adverse events during the 30-day period after the qualifying procedure was performed.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intervention4/525 (0.8%)113/525 (21.5%)0/525 (0%)
Baseline4/1,272 (0.3%)186/1,272 (14.6%)0/1,272 (0%)
Most frequent serious events
Most frequent serious events
EventInterventionBaseline
Emergency Department, Urgent Care Clinic, or Hospital Re-admission within 30 days of the procedureSurgical and medical procedures113/525186/1272

Baseline characteristics

Age, Continuous
Age, Continuous(Years)InterventionBaselineTotal
Mean71.9 ± 10.471.6 ± 10.071.7 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)InterventionBaselineTotal
Female154459
Male51012281738
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)InterventionBaselineTotal
Hispanic or Latino193655
Not Hispanic or Latino45511751630
Unknown or Not Reported5161112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)InterventionBaselineTotal
American Indian or Alaska Native123
Asian167
Native Hawaiian or Other Pacific Islander415
Black or African American97155252
White37810261404
More than one race000
Unknown or Not Reported4482126
Transurethral resection of a bladder tumor
Transurethral resection of a bladder tumor(Participants)InterventionBaselineTotal
Count of participants2827311013
Transurethral resection of prostate
Transurethral resection of prostate(Participants)InterventionBaselineTotal
Count of participants130260390
Ureteroscopy
Ureteroscopy(Participants)InterventionBaselineTotal
Count of participants113281394
08

Study locations

3 sites
  • VA North Florida/South Georgia Veterans Health System
    Gainesville, Florida 32608-1135, United States
  • Iowa City VA Medical Center
    Iowa City, Iowa 52246, United States
  • VA New York Harbor Healthcare System (Brooklyn)
    New York, New York 10010, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jul 2023, 11 months.

Results were first posted in Sep 2024, 1 year 1 month after primary completion.

Of 47 non-industry interventional studies with no phase under Urologic Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's 11 months is below that.

Counting every sponsor, half of 57 studies reached it within 24 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2019
First posted
Dec 12, 2019
StartActual
Aug 1, 2022
Primary completionActual
Jul 31, 2023
CompletionActual
Aug 31, 2023
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04196777
Lead sponsor
Iowa City Veterans Affairs Medical Center
Responsible party
Daniel Livorsi (Principal investigator, Iowa City Veterans Affairs Medical Center) — Principal investigator
First posted
Dec 12, 2019
Start date
Aug 1, 2022
Primary completion
Jul 31, 2023
Completion
Aug 31, 2023
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion